Abstract

Obesity is a risk factor in cardiovascular disease (CVD), and scalable treatment approaches are needed in routine care. The aim of this retrospective observational study was to investigate self-reported weight change during the use of a prescription digital therapy for multimodal lifestyle therapy for obesity. Adults with obesity and self-reported CVD risk factors (n = 4314) or self-reported established CVD (n = 1418) prescribed zanadio for up to 12 months were included. The primary outcome was percentage change in self-reported body weight over time. Clinically meaningful weight loss (≥5%) was observed in patients on continued prescriptions, with greater weight loss observed in patients with prolonged program exposure. The results were directionally consistent across analyses that used a randomly missing approach and a sensitivity analysis with the last observation forward, although estimates varied in magnitude. Interpretation of this data in a real-world setting is limited by self-reported weight and comorbidity data, attrition which is typical for weight loss programs in the reality of care, and uncertainty about the mechanism of missing data. These results suggest that zanadio may support clinically meaningful self-reported weight loss in patients continuing treatment, but further studies linking clinical data and with longer follow-up are needed.

IPC Classification

Keywords